Bosman Van Zaal and Delphy signed a memorandum of understanding (MOU) at the end of 2021 with Cannabizta B.V. with the aim of developing and producing world-class cannabis-based medicines for the growing demand for medical cannabis in the health industry in Asia, starting with the legalised market in Thailand.
Cannabizta B.V. is combining Dutch technology and knowledge with regional investors to establish a viable and innovative cannabis industry for the supply of the fast-growing markets in Asia, mainly Thailand, Korea and Japan. The signing of the MOU is in line with an international conference on the need for medical cannabis in Thailand, which was attended by experts from several countries.
The Thai Medical Services Department is playing a pivotal role in research into and development of herbs and cannabis-based medicines in Thailand, in an effort to enable patients to get access to alternative medications. The Thai Food and Drug Administration has, so far, approved 218 formulae for cannabis and hemp-based cosmetics, such as skin and body care products.